Research location
Garden Grove
California, United States
Research activity in Garden Grove
California, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 403 trials and 407 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Garden Grove
403 linked trials · page 2 of 9A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionNCT06372210 · 2023-06-26 · 1 site observation
COMPLETED
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005NCT05779241 · 2023-04-13 · 1 site observation
COMPLETED
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of SchizophreniaNCT05838625 · 2023-03-31 · 1 site observation
COMPLETED
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic MedicationNCT05741528 · 2023-03-31 · 1 site observation
COMPLETED
A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With SchizophreniaNCT05693935 · 2023-01-24 · 1 site observation
COMPLETED
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-DiabetesNCT05623189 · 2022-12-27 · 1 site observation
COMPLETED
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic MedicationNCT05628103 · 2022-12-19 · 1 site observation
COMPLETED
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)NCT05686239 · 2022-12-08 · 1 site observation
COMPLETED
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 · 2022-11-21 · 1 site observation
COMPLETED
A Trial of the Safety and Efficacy of SEP-363856 in the Treatment of Adults With Major Depressive DisorderNCT05593029 · 2022-11-09 · 1 site observation
COMPLETED
Phase 2 Study of INV-202 in Patients With Diabetic Kidney DiseaseNCT05514548 · 2022-10-19 · 1 site observation
COMPLETED
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With SchizophreniaNCT05443724 · 2022-09-01 · 1 site observation
TERMINATED
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)NCT05406440 · 2022-07-12 · 1 site observation
COMPLETED
7-week Study With CT-155 in People With SchizophreniaNCT05486312 · 2022-07-05 · 1 site observation
COMPLETED
A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaNCT05227690 · 2022-06-30 · 1 site observation
COMPLETED
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyNCT05211947 · 2022-03-21 · 1 site observation
TERMINATED
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05304767 · 2022-03-07 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With SchizophreniaNCT05182476 · 2021-12-07 · 1 site observation
TERMINATED
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDDNCT05165394 · 2021-11-30 · 1 site observation
COMPLETED
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular PressureNCT05165290 · 2021-11-29 · 1 site observation
UNKNOWN
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for SchizophreniaNCT05110157 · 2021-11-29 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation
COMPLETED
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)NCT05103332 · 2021-11-05 · 1 site observation
COMPLETED
Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's DiseaseNCT05074498 · 2021-10-08 · 1 site observation
COMPLETED
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)NCT04846868 · 2021-09-08 · 1 site observation
COMPLETED
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective DisorderNCT05321602 · 2021-09-08 · 1 site observation
COMPLETED
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive MedicationNCT04937829 · 2021-07-20 · 1 site observation
COMPLETED
Lumateperone for the Prevention of Relapse in Patients With SchizophreniaNCT04959032 · 2021-07-08 · 1 site observation
COMPLETED
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)NCT04820309 · 2021-06-02 · 1 site observation
COMPLETED
Tivanisiran for Dry Eye in Subjects With Sjögren's SyndromeNCT04819269 · 2021-05-25 · 1 site observation
COMPLETED
A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-3)NCT04738123 · 2021-04-06 · 1 site observation
COMPLETED
A Clinical Trial of PRAX-114 in Participants With Major Depressive DisorderNCT04832425 · 2021-03-30 · 1 site observation
COMPLETED
Comparative Bioavailability of Risperidone.NCT05179525 · 2021-03-09 · 1 site observation
COMPLETED
An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)NCT04659174 · 2021-02-01 · 1 site observation
COMPLETED
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of SchizophreniaNCT04712734 · 2021-01-13 · 1 site observation
COMPLETED
Relative Bioavailability of LY03010 Compared to Listed DrugNCT04922593 · 2021-01-13 · 1 site observation
COMPLETED
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)NCT04624243 · 2020-12-15 · 1 site observation
COMPLETED
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With DepressionNCT04521478 · 2020-11-20 · 1 site observation
COMPLETED
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionNCT04630808 · 2020-11-09 · 1 site observation
COMPLETED
A Study of TAK-071 in People With Parkinson DiseaseNCT04334317 · 2020-10-21 · 1 site observation
COMPLETED
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With SchizophreniaNCT04510298 · 2020-10-15 · 1 site observation
COMPLETED
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye DiseaseNCT04391894 · 2020-10-06 · 1 site observation
COMPLETED
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive DisorderNCT04479852 · 2020-09-30 · 1 site observation
COMPLETED
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant TherapyNCT04513912 · 2020-09-15 · 1 site observation
COMPLETED
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)NCT04524403 · 2020-09-09 · 1 site observation
COMPLETED
A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective DisorderNCT04512066 · 2020-09-08 · 1 site observation
COMPLETED
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic TreatmentNCT04421456 · 2020-08-18 · 1 site observation
TERMINATED
A Study to Evaluate the Efficacy of Sage-217 in the Treatment of Adult Participants With Major Depressive Disorder (MDD)NCT04442490 · 2020-05-12 · 1 site observation
COMPLETED
Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive DisorderNCT04285515 · 2020-02-27 · 1 site observation
COMPLETED
Study in Major Depressive Disorder With NMRA-335140 (BTRX-335140) vs PlaceboNCT04221230 · 2020-01-03 · 1 site observation
COMPLETED
How to interpret this record
CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.